Program
Anti-GPRC5D Monoclonal Antibody SAR446523
In Sanofi’s pipeline, GPRC5D mAb
. Its studies are mostly in Multiple Myeloma, led by Sanofi.
Furthest: phase 1, since Oct 3, 20241 company-led study, 1 open or runningNext primary completion: May 16, 2031 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 1since Oct 3, 2024 | Oct 3, 2024 | May 16, 2031phase 1 · NCT06630806 |
- Named in Sanofi’s own pipeline as
SAR446523
, phase 1, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 3, 2024First study: phase 1 study in Plasma Cell Myeloma RefractoryFirst studyNCT06630806 · 87 planned · United States, Australia, Canada and more
Ahead
- May 16, 2031Primary completion: phase 1 study in Plasma Cell Myeloma RefractoryNCT06630806
TargetBeta
“GPRC5D mAb”the company's pipeline, read by Claude · source
“A Fc-engineered immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human G-protein coupled receptor family C group 5 member D (GPRC5D), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GPRC5D monoclonal antibody…”NCIt, read by Claude
Other programs on GPRC5D
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 8 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| arlocabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 3 |
| QLS4131rule | Qilu Pharmaceutical | phase 3 | 3 |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 2 |
| vemzatatug vedotin | AstraZeneca | phase 2 | 1 |
| MBS314 for Injectionrule | beijing-mabworks-biotech-co-ltd | phase 2 | 1 |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| tunlucabtagene autoleucel | Bristol-Myers Squibb | phase 1 | 1 |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06630806Plasma Cell Myeloma Refractory · United States, Australia, Canada and more | 1 | Recruiting | May 16, 2031 | 87 |
How it is read
Names in the registry
- “SAR446523”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.